MajorTriptan, selective 5HT1B/1D receptor agonist×Triazole derivatives, systemic antifungals
Updated · Methodology
Mechanism
The liver breaks down eletriptan mainly through the enzyme CYP3A4, and the voriconazole label describes voriconazole as a strong inhibitor of this enzyme. No study has looked at this pair directly, but other strong CYP3A4 inhibitors raised eletriptan levels markedly. Ketoconazole 400 mg increased the eletriptan area under the curve (AUC) 5.9-fold and lengthened its half-life from 4.8 to 8.3 hours. Erythromycin 1000 mg increased the AUC 3.6-fold. The voriconazole label says that the rise in another drug's AUC depends on the drug itself. Like other triptans, eletriptan can cause coronary artery spasm. In clinical trials, doses of 60 mg or more caused short-lived rises in blood pressure.
Symptoms
Tightness, pain or pressure in the chest, throat, neck and jaw is common after eletriptan. It is usually not cardiac but can be a sign of coronary artery spasm. Myocardial infarction, ventricular tachycardia and ventricular fibrillation have been reported within a few hours of triptan use, sometimes in people without known heart disease. Rarely, blood pressure rises sharply, even to a hypertensive crisis. Spasm of other arteries can cause abdominal pain with bloody diarrhoea from bowel ischaemia, white and cold fingers (Raynaud's syndrome), or cramping and heaviness in the legs.
Management
The eletriptan summary of product characteristics (SmPC) says not to use eletriptan with strong inhibitors of the enzyme CYP3A4 (Spanish Agency of Medicines and Medical Devices, AEMPS). Voriconazole is a strong inhibitor of this enzyme (voriconazole SmPC, European Medicines Agency, EMA). The eletriptan label of the US Food and Drug Administration (FDA) requires a gap of at least 72 hours after treatment with a strong CYP3A4 inhibitor. Do not recalculate this gap from the voriconazole half-life: voriconazole pharmacokinetics are non-linear, and its half-life does not predict how fast it is cleared (voriconazole SmPC, EMA). If eletriptan has been taken during voriconazole treatment and chest pain or tightness suggesting cardiac ischaemia appears, give no further doses and evaluate the heart (eletriptan SmPC, AEMPS). Stop eletriptan if arrhythmias occur, and monitor blood pressure during treatment (eletriptan label, FDA). If signs of spasm in other arteries appear, such as abdominal pain with blood in the stool or white, cold fingers, rule out vasospasm before the next dose (eletriptan label, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Vfend (voriconazole) prescribing information – CYP3A4 inhibitor, statin/immunosuppressant interactions (2020)– FDA Vfend label, Drug Interactions §7 – tacrolimus, cyclosporine, sirolimus, statins; DailyMed setid ce3ef5cf-3087-4d92-9d94-9eb8287228db
- FDA: Relpax (eletriptan hydrobromide) tablets – prescribing information (2024)– FDA label, Viatris Specialty, DailyMed setid 2a501dbd-3ea8-47e4-9fcb-07035b8c8c9e, version 4, 01/2024, sections 4, 5.7, 7.1, 7.2 and 7.3
- EMA: Ficha técnica: Voriconazol (EU/1/02/212), sección 4.5 (2026)– EMA SmPC vía AEMPS CIMA, nº 02212015 (EU/1/02/212), secciones 4.2, 4.4 y 4.5, consultado 10/2026
- AEMPS: Ficha técnica: Eletriptán (nº registro 64124), sección 4.5 (2024)– AEMPS, CIMA, nº registro 64124 (Relpax 20 mg, Viatris), revisión 05/2024, secciones 4.4 y 4.5